TransCelerate BioPharma Inc. has selected DrugDev to develop and host its Investigator Registry
TransCelerate BioPharma Inc. has selected DrugDev to develop and host its Investigator Registry, which will allow TransCelerate member companies to pool investigator data together into a centralized, cloud-based resource utilizing a universal identifier known as the DrugDev Golden Number. The registry, along with TransCelerate’s Shared Investigator Platform, will help streamline some of the more inefficient clinical trial processes by offering the ability to expeditiously find investigator matches for their trials will drive improved performance.
For investigators, the registry expands their access to clinical trial opportunities by making them known throughout participating TransCelerate Member Companies. Moreover, making their investigator and site profile information available in the registry reduces the number of basic site information requests, which in turn allows them to spend more time focused on clinical activities.
DrugDev also is the third party host of the Investigator Databank.
Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.